Introduction
Reactivation of the tissue cyst of Toxoplasma gondii is the major pathogenic event in the development of toxoplasmic encephalitis (TE) in AIDS patients and of ocular disease in individuals with congenitally acquired toxoplasmosis (CT). Definitive diagnosis of TE is rarely achieved and in AIDS patients follows the onset of symptoms associated with central nervous system (CNS) involvement. Definitive diagnosis in this patient group requires brain biopsy and either histological demonstration or culture of parasites [l] . A confirmed diagnosis of ocular toxoplasmosis requires extended ophthalmic supervision with prompt treatment in periods of acute exacerbation [2] . The anti-protozoal agents used in the treatment of these patient groups have toxic effects, precluding prolonged prophylactic use. Timely therapeutic intervention before the development of symptoms would be considered highly desirable, leading to major reductions in morbidity and permanent disability.
Serodiagnosis for monitoring of primary toxoplasmosis is well established; assays use the tachyzoite as the principal antigen [3]. However, these tests do not discriminate an asymptomatic latent infection from reactivating disease, even though both bradyzoite and 
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tachyzoite stage specific [4] and shared [5] antigens are detectable during the development of an immune response in reactivating toxoplasmosis. In most AIDS patients serological evidence of previous I: gondii infection is seen before the onset of encephalitis. However, following onset of symptoms only a minority of patients with AIDS and TE demonstrate a significant change in anti-tachyzoite IgG or IgM antibody titre, or both [l] . Thus, a serological test capable of discriminating between active and quiescent toxoplasmosis in this population would provide a significant improvement in diagnosis and treatment. Suzuki and Remington [3] proposed that membranebound formalin-fixed tachyzoite antigens improved the serodiagnosis of TE in patients with AIDS. Their study discriminated between patients with TE demonstrated at biopsy and ambulatory patients asymptomatic for CNS diseases, but was not tested as a predictive assay for the onset of TE.
The hypothesis that antibody recognition of I: gondii tissue cyst-derived antigen (as distinct from tachyzoite-derived antigen) is a good indicator of reactivation disease was tested. The assumption is made that the reactivating tissue cyst presents both cyst wall/ matrix and bradyzoite-derived antigens to immune surveillance as well as tissue cyst-derived tachyzoite antigens [6] . This retrospective study of sera from patients with acute and quiescent toxoplasmosis considered AIDS patients and patients with ocular disease separately, as the exposure to parasite antigens may be different in these two groups. The hypothesis has been tested by the development of a new enzyme-linked immunosorbent assay (ELISA) for antibody to cyst antigens and screening of cyst antigens by Western blot analysis.
Materials and methods

Patients
Sera were selected from the PHLS Toxoplasma Reference Unit serum bank. Three groups were studied.
( 1) Immunocompetent patients with no ocular disease presenting for investigation of lymphadenopathy, monospot negative glandular fever or other non-specific disease; T gondii sero-negative and I: gondii seropositive. (2) Patients with active or quiescent ocular toxoplasmosis and serologically confirmed exposure to the parasite. Active ocular disease was defined as those patients with evidence of inflammation on retinal examination. Quiescent ocular toxoplasmosis was defined as those patients with clinical evidence of retinal lesions characteristic of T gondii infection in the absence of active inflammation (i.e., evidence of previous but not current reactivation). (3) HIV positive patients, with active cerebral toxoplasmosis or with quiescent toxoplasmosis. Active cerebral toxoplasmosis was defined as: compatible clinical presentation, SabinFeldman dye test positive, compatible computerised tomographic scan and subsequent response to specific therapy.
Antigen preparations
For preparation of I: gondii tissue cysts, Sau strain [7] was maintained in C57/BL10 mice as described by Roberts and Alexander [8] . After 4 weeks the mice were killed and brains were removed and homogenised in a Dounce homogeniser with 2ml of sterile phosphate-buffered saline (PBS). Tissue cysts were then purified on pre-formed Percoll gradients, 45% v/v in PBS (1250 g, 30 min, room temperature) [9] , washed three times and resuspended in PBS. Tissue cysts were counted and the preparation was stored as a pellet at -70°C. In the order of 20000-50000 tissue cysts/ mouse brain were recovered. Complete rupture of tissue cysts was ensured before use; the pellet was resuspended in 500 pl of distilled water and submitted to five cycles of freezing in a methanol-dry ice bath and thawing at 37°C. The suspension was then sonicated at 50 cycles/s for 30 s on ice; tissue cysts were checked microscopically for rupture. Sonication was repeated until complete rupture was observed.
RH strain tachyzoites were passaged in MF1 mice as described previously [ lo] . Parasites were washed three times, resuspended in PBS, counted and stored as a pellet at -70°C.
Quantitative serology
All serum samples were assessed for the presence of I: gondii-specific antibody by the Sabin-Feldman dye test [ 113. Seropositivity was defined as a dye test result of 2 2 IU.
IgM was measured by a double sandwich ELISA (DS-ELISA) and an immunosorbent agglutination assay (ISAGA) [12] .
An ELISA for the presence of I: gondii tissue cystspecific antibody was developed. Falcon flat-bottomed microtitration plates were coated at 4°C overnight in a humidity chamber with tissue cyst suspension diluted to 20 tissue cysts/well in Na2C03 /NaHC03 coating buffer (0.05 M, pH9.6). Plates were washed once with PBS, then three times with PBST (PBS, Tween 20 0.5%) for 5 min each. Patient sera were diluted 1 in 1000 in PBST containing goat serum 1% and 100 pullwell were incubated for 1 h, at 37°C in a humidity chamber. Plates were washed three times with PBST for 5 min each and then incubated with 100 pl of goat anti-human horseradish peroxidase conjugate (Sigma) diluted 1 in 10000 in goat serum in PBST 1% for 1 h at 37°C in a humidity chamber. Plates were washed four times with PBST for 5 min each before developing with tetramethylbenzidine (TMB) in acetate buffer (0.1 M sodium acetate, 0.1 M citric acid, pH6.0) and hydrogen peroxide at a final concentration of 0.5% v/v. Absorbance was measured at 450 nm on a Titretek Multiskan MCC/340 ELISA plate reader. Results were expressed as enzyme immunoassay units (EIU) calculated as described by Balfour [ 131.
Data were expressed as box and whisker plots and tested for statistical significance by the Mann-Whitney U test (Unistat, Unistat Ltd).
Western blot analysis
Either tissue cyst antigen (10000 tissue cysts/gel) or tachyzoites (1.4 X 1 O7 parasites/gel) were heated at 100°C in reducing buffer for 10 min before separation on a polyacrylamide 12.5% gel [14] . After SDS-PAGE separation proteins were transferred electrophoretically to nitrocellulose at 400 mA for 1 h. Filters were cut into strips and blocked for 1 h at room temperature with non-fat milk 5% in Tween-Tris buffered saline (TTBS; 1 M TrisHCl, NaCl 0.9%, Tween 20 0.1%). After three washes in TTBS (5 min, RT) individual strips were incubated with patient sera diluted 1 in 100 in TTBS containing goat serum 10%. Incubation was for 15 min at RT with continual rocking. Strips were washed as described previously and incubated with the second antibody, biotinylated goat anti-human IgG whole molecule (Amersham) diluted 1 in 1000 in goat serum 10% in TTBS for 15 min at RT. Again the strips were washed and then incubated with strepavidinalkaline phosphatase conjugate (Boehringer Mannheim) diluted 1 in 2000 in TTBS for 15 min at RT. Strips were washed four times and antigens were visualised with nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) substrate following the manufacturer's instructions.
Results
A total of 187 sera was studied by both dye test and tissue cyst ELISA (Table 1) . The quiescent sera tested included samples from patients treated for a previous episode of active toxoplasmosis. Our definition of quiescence may be more correctly defined as 'post-treatment quiescence' and antibody responses in this group may be distinct from patients with no previous reactivation and may be more like active disease. Discrimination between these two categories would require anti-I: gondii antibody levels to fall in quiescence. However, dye test data and the dynamic tissue cyst model suggest that levels are maintained; furthermore, the Western blot data also demonstrate no qualitative change. To establish the precise relationship between 'post-treatment quiescence' and 'no reactivation quiescence' a prospective study following the serological outcome of congenital toxoplasmosis would be necessary. This approach would enable the identification of early reactivation events; however, ethical considerations may exclude the possibility of such a study.
In designing an ELISA specific for T. gondii tissue cyst antigens, the aim was to establish whether the deregulated reactivation associated with either HIV or and active toxoplasmosis (n = 42; 0). ocular disease was associated with a quantitative stage expresses fewer antigens than the tachyzoite and change in tissue cyst-specific antibody. A whole tissue that the immune response to these antigens is lower. cyst preparation was adopted which included tissue Of the sera studied, the only population to be cyst wall, tissue cyst matrix and bradyzoite antigens. markedly different from the others was the sera from The evidence from both the present study and immunocompetent I: gondii seropositive patients previous authors [21] indicates that this life cycle exposure to tachyzoites and the increase in anti-tissue cyst antibody level may reflect recognition of epitopes that are common to both tachyzoites and bradyzoites [5] or exposure to the intermediate steps of tachyzoitebradyzoite interconversion [ 61, or both, reflecting the dynamic equilibrium between tachyzoites and tissue cysts. The contribution of shared epitopes to the antitissue cyst antibody level may be addressed in future studies by the pre-absorption of sera with tachyzoites. Furthermore, tissue cysts may form early in an infection such that immunocompetent patients, even in the acute phase of infection, will have been exposed to tissue cyst antigens. Thus, patients with both recently acquired and long-standing infections will respond to tissue cyst antigens, although, as Zhang et al. [21] demonstrated, anti-tissue cyst antibody titres rise slowly in comparison to antitachyzoite antibody titres.
HIV-positive quiescent samples had raised I: gondii tissue cyst-specific antibody levels. However, in both populations of patients with active toxoplasmosis (HIV positive or ocular disease), levels of tissue cystspecific antibody titres were similar to those of T gondii seronegative sera. Failure of patients with chronic exposure to I: gondii to recognise tissue cyst antigens may be a result of antigens not being exposed to the host immune system; tissue cysts are located primarily in sites regarded as being immune privileged. Furthermore, Western blot analysis of tissue cyst antigens with sera from cyst immunised mice [unpublished observations, 221 reveals six-toeight antigens, suggesting that tissue cysts display only a limited set of antigens and do not elicit a complex immune response. This observation corresponds to the histological evidence that immune infiltration occurs only after tissue cyst rupture [17] and the view that I: gondii has a preference for sites which are immunologically privileged [23] . Thus, the tissue cyst is concealed from host immune surveillance until the actual event of reactivation. The cyclic reactivation proposed above presents a trickle of predominantly tachyzoite antigens to the host. The principal immunogens associated with reactivation are thus tachyzoite-derived, as demonstrated by the dye test data and not tissue cyst or bradyzoite-derived as demonstrated by the ELISA. Therefore, anti-tissue cyst antigen antibody levels are not a good correlate of reactivation in AIDS.
The tissue cyst ELISA did demonstrate a significant difference in tissue cyst-specific antibody level in the two HIV-positive categories. The patients with active disease demonstrated lower titres than those in quiescence. It may be that this observation is a reflection of the immunocompromised status of the patients in the active disease group; total antibody levels in this cohort will be reduced and thus tissue cyst-specific antibody may also be proportionately depleted. However, the corresponding dye test values for this group did not reflect such a depletion (Fig. 1) . The apparent disparity between tissue cyst ELISA and dye test levels may be associated with an impaired ability of HIV-positive patients to process novel antigens resulting from tisssue cyst turnover. Reactivation occurs in the period when immunosuppression of the HIV positive patient is most apparent [15] . The results may indicate that tissue cyst antigens generate only short-term immunological memory rather than the long-term memory for tachyzoite antigens demonstrated by the dye test, resulting in no apparent decrease in response to the dye test at this stage of HIV infection. Alternatively, disparity in the response of these two groups may correspond to the variation in degree of immunosuppresion between the groups. However, in this retrospective study HIV-positive sera were not CD4+ scored, as ethical approval had not been sought. Thus, anti-cyst antigen titre cannot be correlated with CD4+ count to clarify the role of the extent of immunosuppression in the difference between HIV-positive active and quiescent sera, although previous studies indicate that TE is usually associated with CD4+ counts < 200 cells/mm3 [ 151.
Data from patients with reactivating ocular toxoplasmosis demonstrate that tissue cyst-specific antibody levels do not differ in active and quiescent disease and indeed they are not significantly different from immunocompetent I: gondii seronegative sera. This may reflect the concealed nature of the tissue cyst antigens and release of antigenically distinct life cycle stages on reactivation. This study did not distinguish between patients with documented CT and those with acquired infection leading to ocular disease. However, this sample is likely to contain predominantly patients with CT, as in a UK population the majority of patients with ocular toxoplasmosis are infected as a result of congenital infection. Thus, the inability of an apparently immunocompetent population to recognise tissue cyst antigens may be a result of infection in utero followed by invasion of immune privileged sites and concealment of the parasite before the full development of the neonatal immune system. It is also possible that patients who develop ocular toxoplasmosis represent a population distinct from acquired toxoplasmosis patient groups because of either partial immunosuppression or tolerance.
The data in Fig. 2 do identify immunocompetent patients as having raised anti-tissue cyst titres. This observation may be of use in characterising genuinely latent forms of toxoplasmosis in which 'healthy carriership' is identified. This approach may enable the distinction between chronic quiescent infection and active, non-symptomatic infection where a differential diagnosis is being sort for such conditions as chronic fatigue syndrome.
Interpretation of the quantitative data indicating that chronic toxoplasmosis reflects a dynamic situation in which the host is exposed to a limited range of immunogens which are largely shared with tachyzoites is confirmed by the Western blot data presented here and by previous authors [4, 23] . In this analysis of 57 patient sera, few antigens were recognised by more than one-third of the sera and no single antigen was diagnostic of quiescence or active disease. This study adopted a single strain as the source of antigen both for ELISA and Western blot. Strain variation has been demonstrated by Ware and Kasper [24] and Woodison [22] . However, the differences noted by these authors were limited and the major immunogens were conserved, such as the 36-kDa antigen described in this study, by Woodison [22] and by Tomavo [25] . The present study demonstrated eight antigens (65, 57, 49, 47, 36, 28, 26 and 18 kDa) which are consistently recognised by one-third or more of the sera tested. This limited number of antigens is in agreement with other authors and the molecular mass of these antigens is also comparable with those described previously [4, 23, 25] .
In conclusion therefore, tissue cyst-derived antigens are not a reliable serological marker to distinguish active from post-active reactivating toxoplasmosis. The current study was performed with groups of patient sera. It is feasible that the analysis of serial samples from individuals before their first reactivation event may identify specific antigens associated with reactivation. However, the dynamic model of tissue cyst maintenance proposed here would not predict this outcome. This study failed to identify a single immunogen that was diagnostic of reactivation, but this should not preclude study of candidate molecules as they are identified through alternative strategies. However, this study provides support for the model of 7: gondii tissue cysts as a dynamic population undergoing a cyclical and continuous turnover under immune control and for the proposal that reactivation reflects the deregulation of this process.
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